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Background: Pregnant women with mild gestational hyperglycemia present high risk for hypertension, obesity and
hyperglycemia, and appeared to reproduce the model of metabolic syndrome in pregnancy, with hyperinsulinemia
and insulin resistance. Our clinical studies showed that mild gestational hyperglycemia or gestational diabetes are
related to similar adverse maternal and perinatal outcomes. Hyperglycemia and other factors associated with
diabetes generate reactive oxygen species that increase DNA damage levels. The aim of this study was to evaluate
oxidative DNA damage in lymphocytes of pregnant women with diabetes or mild gestational hyperglycemia.
Methods: The study included 111 pregnant women distributed into three groups based on oral glucose tolerance
test (OGTT) and glycemic profiles (GP), as follows: Normal OGTT and GP (control group); Normal OGTT and
abnormal GP (mild gestational hyperglycemia group); Abnormal OGTT and GP (diabetic group). Maternal blood
samples (5–10 mL) were collected and processed for determination of oxidative DNA damage by the comet assay,
using Fpg and Endo III enzymes. Urine samples were also collected for determination of 8-OHdG concentrations by
ELISA.
Results: Subjects in the diabetes group presented increased amount of oxidized purines, while mild gestational
hyperglycemia women presented with increased oxidized pyrimidines, compared to the control group.
Conclusion: Gestational, overt diabetes and mild gestational hyperglycemia, were all related to increased oxidative
DNA damage. Diabetic pregnant women showed increased level of oxidative DNA damage, perhaps mainly due to
hyperglycemia. On the other hand, oxidative DNA damage detected in women with mild gestational
hyperglycemia might be associated with repercussions from obesity, hypertension and/or insulin resistance.
Interestingly, the type of DNA base affected seemed to be dependent on the glycemic profile or oxidative stress.
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The Hyperglycemia and Adverse Pregnancy Outcome
(HAPO) Study has demonstrated significant perinatal
risks at levels of maternal hyperglycemia below values that
are diagnostic for diabetes [1]. Furthermore, this study has
confirmed our previous findings showing that glycemia
lower than GDM (Gestational Diabetes mellitus) is also
related to adverse perinatal outcome [2]. The new criteria* Correspondence: marilzarudge@gmail.com
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unless otherwise stated.for diagnosis of GDM identified a group of women
that were previously classified as normal according to the
4th International Workshop Conference criteria [3]. This
group has metabolic characteristics and pregnancy out-
comes resembling women who would have been consid-
ered to have GDM by previous criteria.
Since 1990, Rudge et al. [4] have combined two paral-
lel diagnostic tests, 100 g Oral Glucose Tolerance Test
(OGTT) and Glycemic Profile (GP), to characterize the
mild gestational hyperglycemia (MGH) pregnant group,
women with positive screening for GDM, negative diag-
nosis for GDM but with hyperglycemia detected in the
GP. In diurnal GP the fasting plasma glucose, 1–h over
a 2-h period post-ingestion of general diet are collected.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pregnant women for GDM and, added to 7.0% of preg-
nancies complicated by diabetes, increase the occurrence
of hyperglycemic disorders in pregnancy to about 20%
[5]. These patients were at high risk for hypertension,
obesity and hyperglycemia, and appeared to reproduce
the model of metabolic syndrome (MS) in pregnancy,
with hyperinsulinemia and insulin resistance, which con-
tinued six weeks postpartum [6]. After 10 to 12 years of
the index-pregnancy, type 2 diabetes was confirmed in
16.7% of women with MGH during pregnancy [7]. Ex-
ploratory analyses with newborn outcomes indicated
53.8% with macrosomia, a similar proportion (51.9%) to
that described for overt diabetes and GDM [8]; a high
perinatal mortality rate (41%) was also similar to that ob-
served in diabetic women and was10 times greater than
that of normal pregnant women [9]. These newborns may
also exhibit hypoglycemic crises, hyperbilirubinemia and a
high incidence of prematurity and congenital anomalies
[2]. Therefore, despite being identified in the literature as
low-risk, MGH in pregnancy is associated with adverse
maternal and perinatal outcomes, previously classifiable as
normal according to the 4th International Workshop Con-
ference criteria. Furthermore, MGH patients represent a
significant public health problem and must be reclassified
as abnormal according to maternal and perinatal findings
[9]. Therefore, it is crucial to understand the underlying
mechanisms involved in MGH in order to detect If MGH
and GDM are the same disease in different stages or are
different pathologies with similar maternal and perinatal
results. This is important since the stimuli to detect
hyperglycemia and MGH are different. In GDM hyper-
glycemic levels are detected after ingestion of 75 g of
glucose and in MGH hyperglycemia is detected after in-
gestion of a general diet.
Type 2 diabetes is the most common endocrine disorder
affecting more than 5% of the population in western coun-
tries [10]. The pathogenesis of type 2 diabetes is character-
ized by both decreased peripheral insulin action and
impaired pancreatic β-cell function [11,12]. In the majority
of the prediabetic population, the earliest abnormality is
insulin resistance that precedes the development of glu-
cose intolerance [13]. Initially, the pancreas attempts to
compensate for insulin resistance through increased insu-
lin secretion. When the pancreas is unable to maintain a
sufficient hyperinsulinemic response, frank diabetes en-
sues as a consequence of progressive loss of β-cell func-
tion. Patients with type 2 diabetes are also characterized
by reduced β-cell mass as compared with weight-matched
non-diabetic subjects [14].
Animal models have confirmed the human epidemio-
logic findings and elucidated potential programming
mechanisms of MGH, that include altered organ devel-
opment, cellular signaling responses, and epigeneticmodifications. Using an animal model, we have shown that
rats with mild (glycemia from 120 to 300 mg/dL) or severe
(glycemia > 300 mg/dL) diabetes and their newborns ex-
hibited increased oxidative DNA damage detected by the
comet assay [15]. Increased levels of DNA damage have
been previously observed in leukocytes of type1 diabetes
and type 2 diabetes patients [16-18]. Dinçer et al. [17]
have confirmed increased DNA damage and sensitive FAP
glycosylase restriction sites in type 1 diabetes, and Pitozzi
et al. [18] have detected increased oxidative DNA damage
in polymorphonuclear leukocytes from type 2 diabetes.
Other clinical and experimental investigations have also
shown the presence of DNA oxidative damage in diabetic
patients [19-21]. Diabetes and hyperglycemia can be
sources of DNA damage via the oxidation of DNA bases
and sugar-phosphate binding sites [22].
Therefore, since our clinical studies showed that GDM
or MGH are related to similar adverse maternal and
perinatal outcomes, and the animal models demon-
strated increase oxidative DNA damage in moderate and
severe diabetic rats, we hypothesized that even though
not diagnosed with diabetes, MGH pregnant women
might have increased levels of this genotoxic event. If
this hypothesis is correct, overt diabetes, GDM or MGH
can each contribute to DNA damage and represent dif-
ferent stages of the same pathology. The aim of the
present study was to evaluate oxidative DNA damage in
lymphocytes from pregnant women with a wide range of
glucose tolerance. Using different restriction enzymes,
this manuscript demonstrated different answer accord-
ing to glycemic variation and others factors associated to
diabetes in pregnant women with diabetes or mild gesta-
tional hyperglycemia.
Research design and methods
After approval by the Research Ethics Committee of Botucatu
Medical School number (OF 545/2004) the present
investigation was conducted at Perinatal Diabetic Research
Center - Botucatu Medical School, UNESP, Brazil. This
study included 111 pregnant women. The pregnant women
were assigned to participate if they presented with a fasting
glycemia level ≥90 mg/dL and/or risk factors for develop-
ing gestational Diabetes mellitus between the 24th and
28th week of gestation. A 75 g oral glucose tolerance test
(OGTT) and a glycemic profile were performed; the cutoff
values for the OGTT were those proposed by Carpenter &
Coustan (fasting ≥95 mg/dL; 1 h ≥ 180 mg/dL; 2 h ≥
155 mg/dL;) and for the glycemic profile, those proposed
by Gillmer et al. (fasting ≥ 90 mg/dL and/or postprandial ≥
130 mg/dL) (Additional file 1 (flowchart)). After these pro-
cedures the patients were classified into three groups:
Normal OGTT and glycemic profile (normoglycemic or
control group) n = 41
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hyperglycemic group-MGH) n = 24
Abnormal OGTT and glycemic profile (diabetic group)
n = 46. (Rudge et al. [4]).
At screening, maternal characteristics such as age, body
mass index (BMI), diabetes and hypertension were re-
corded. Hypertension was considered when a systolic
blood pressure >140 mmHg and/or a diastolic blood pres-
sure > 90 mmHg, on at least two occasions at least six
hours apart, was detected [13]. For maternal hyperglycemia
regulation, pregnant MGH and GDM women were treated
with diet, physical exercise, and insulin therapy (if neces-
sary) after the diagnosis, and women with type 2 diabetes
were treated since the beginning of pregnancy [23,24].
Inclusion criteria were defined: (a) classified in the
study groups, (b) gestational age of entry into treat-
ment’s protocol of 30 weeks for MGH and 20 weeks
pregnant for type 2 DM (c) prenatal care and birth on
the service, (d) consent form signature. Exclusion criteria
were multiple pregnancies, fetal malformations, birth be-
fore 34 weeks and type 1 diabetes.
The glycemic mean was calculated by the arithmetic
mean of plasma glucose measured in all GP performed at
diagnosis (ND group) and the control of treatment (MGH
and diabetic groups). Plasma glucose was measured by the
glucose oxidase method (Glucose - Analyzer II Beckman®,
Fullerton, California, USA) and the body mass index
(BMI) was calculated by body weight divided by the square
of height.
From 34 weeks of gestation and before the onset of
labor, maternal blood samples (5 to 10 mL) and urine
samples were collected. The blood samples were collected
in Vacutainer tubes with EDTA and the urine samples in
collector tubes. The collected blood samples were imme-
diately processed for determination of oxidative DNA
damage by the comet assay and the urine samples were
stored in a freezer at −80°C for the measurement of
8-OHdG and creatinine levels.
To evaluate oxidative DNA damage, the comet assay
was performed acoording to the protocol described by
Collins et al. [19]. Briefly, maternal lymphocytes were
isolated using a Ficoll® gradient, and 20 μl were mixed
with low melting point (LMP) agarose (120 μl), placed
on a precoated slide with normal melting point (NMP)
agarose, and immediately covered with a coverslip. The
slides were left at 4°C for 10 min to solidify the agarose.
The coverslip was gently removed and the slides were
immersed in an ice-cold freshly prepared lysis solution
(2.5 M NaCl, 100 mM EDTA, 10 mM Tris, with 1%
Triton 100-X, and 10% dimethylsulphoxide added just
before use). Afterwards, the slides were washed with
cold PBS (phosphate buffered saline) buffer and 1X
FLARE (Fragment Length Analysis using Repair Enzymes)buffer and placed in a lined container. The enzymatic
treatment was performed following the methodology de-
scribed by Collins et al. [25]. The formamidopyrimidine
DNA glycosylase (Fpg) and endonuclease III (Endo III) en-
zymes were used to detect oxidative damage in purine and
pyrimidine bases, respectively. After enzymatic treatment,
the slides were covered with coverslips and kept at 37°C
for 45 minutes. The coverslips were removed and slides
placed on a horizontal electrophoresis unit filled with
fresh electrophoresis alkaline buffer (300 mM NaOH and
1 mM EDTA, pH > 13). The alkali unwinding duration
was 40 min. Electrophoresis was conducted at 4°C for
30 min at 25 V/cm and 300 mA. All steps were carried
out under minimal illumination. The slides were neutral-
ized in a buffer (0.4 M Tris at pH 7.5) and dipped in
absolute alcohol for fixation. The dried slides were stained
with ethidium bromide (20 μg/ml in distilled H2O; 50 μl/
slide), covered with a coverslip and analysed in a fluores-
cence microscope connected to a computer-based analysis
system (Comet Assay IV, Perceptive Instruments, UK) to
determine the extent of DNA damage. Results were
expressed as tail intensity (% DNA in the comet tail). One
hundred randomly selected nucleoids (50 from each of two
replicate slides) were scored per blood sample. Positive
controls consisted of lymphocytes treated with H2O2
(200 μM, 30 minutes) [26].
The 8-hidroxy-2-deoxi guanosina (8-OHdG) dosage
was determined by ELISA according to the manufac-
turer’s protocol (8-OHdG Kit _EIA, Cayman Chemical
Company). The creatinine measurement was performed
by spectrophotometry (Creatinine assay Kit, Cayman
Chemical Company). After 8-OHdG and creatinine de-
termination, the mass ratio was performed between the
8-OHdG concentration and creatinine levels.
Analysis of variance (ANOVA), followed by the Tukey’s
multiple comparisons test, was used for the characteristic
endpoints of the study population, and the ANOVA
followed by Student Newman-Keuls test for 8-OHdG dos-
ages. To analyze the significance (p < 0.05) of oxidative
DNA damage, Gamma distribution was applied.
Results
Table 1 shows the characteristics (age, body mass index,
glycemic mean, glycated hemoglobin and blood pressure)
of the study population. Age and body mass index (BMI)
did not differ among the groups. Higher glycemic means
were observed in both the MGH and diabetic groups com-
pared to the control group. The glycemic mean in women
of diabetic group was higher than in subjects in the MGH
group (p < 0.05). Glycated hemoglobin was higher in dia-
betic group compared to the control group (p < 0.05). The
MGH group had a greater number of individuals with
hypertension in pregnancy compared to the other study
groups (p < 0.05).
Table 1 Characteristics of the study population
Groups
Control MGH Diabetic
N 41 24 46
Age (years) § 29.7 ± 5.5 31.5 ± 4.2 31.3 ± 5.4
BMI (Kg/m2)§ 32.7 ± 6.9 36.0 ± 7.4 35.2 ± 6.3
Glicemic Mean (mg/dL)§ 81.5 ± 9.5 97.9 ± 7.5* 111.5 ± 17.6*#
HbA1C§ 5.45 ± 0.53 5.74 ± 0.67 6.33 ± 0.90*#
Rate of Hypertension (N)%))|| 14 (34.1) 16 (66.6.)*& 17 (35.4)
HbA1C – Glycated Hemoglobin.
Data presented as mean ± standard deviation and number of
subjects (percentage).
*p < 0.05 – significant difference compared to the control group
(§Tukey’s multiple comparison test and ||chi-square test).
#p < 0.05 – significant difference compared to the MGH group
(Tukey’s multiple comparison test).
&p < 0.05 – significant difference compared to the diabetic group
(chi-square test).
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(FPG) (tail intensity) in lymphocytes from women with DG,
compared to women in the control group (Figure 1) and an
increased level of oxidized pyrimidines (EndoIII) (tail inten-
sity) in lymphocytes from women with MGH compared to
the control group (Figure 2). Regarding the concentration
of 8-OHdG in urine, it was slightly increased in pregnant
women with diabetes and MGH, although no statistically
significant difference was detected (p > 0.05) (Figure 3).
When using the restriction enzyme Endo III, women
in the MGH group with hypertension had higher values
of oxidative DNA damage compared to those in the
MGH group without hypertension (70.15 ± 8.7 vs. 53.74 ±
17.4) (p = 0.05).
Positive controls treated with H2O2 presented levels of
DNA damage (tail intensity) of 77.82 ± 5.3 (mean ± stan-
dart error of the mean).
There are no reports about the ethnic differences in
the comet assay and DNA damage.Figure 1 Oxidative DNA damage levels after treatment using enzyme
Data presented as mean ± standard error of mean. *p < 0.05 – significant dDiscussion
The available literature provides insufficient information
on the involvement of DNA damage in pregnant women
with a wide range of glucose tolerance, diabetes and
MGH. The hyperglycemia seen in type 2 diabetes is asso-
ciated with increased oxidative stress and production of
reactive oxygen species, both of which are factors that can
induce DNA damage. Therefore, the aim of this study was
to evaluate oxidative DNA damage in lymphocytes from
pregnant women with a wide range of glucose tolerance.
In this report, we demonstrate increased levels of oxidized
purines and pyrimidines in diabetic and MGH subjects,
respectively, compared to control mothers.
Our findings in the diabetic pregnant group are con-
sistent with those reported by Collins et al. [19], in their
classical study, showing that oxidized purines specifically
reflect DNA damage caused by hyperglycemia. There-
fore, Fpg-sensitive sites were more closely associated
with increased glycemic levels. In our translational study,
similar results were found in diabetic pregnant rats [27].
To the best of our knowledge, the current data showing
high level of oxidized pyrimidines in the MGH group is
described for the first time. FPG sensitive-sites were not
increased in these women. This MGH group presented
not only with hyperglycemia but also with insulin resist-
ance, obesity and hypertension [28], which have already
been associated with increased DNA damage [29-31].
High insulin resistance indices (HOMA-IR) can infer
oxidative stress and DNA damage [32]. Yildiz et al. [29]
and Gür et al. [31] showed that DNA damage caused by
ROS occurs more commonly in hypertensive patients.
The association among mild hyperglycemia, insulin re-
sistance and hypertension may be related to the high
level of oxidized pyrimidines presented in lymphocytes
from women in the MGH group. Collins et al. [19]
shows that Endonuclease III-sensitive sites are not corre-
lated with glycemia; it is possible that reactive oxygenformamidopirimidine glycosylase (Fpg) in the study groups.
ifference compared to the control group (Gamma distribution).
Figure 2 Oxidative DNA damage levels after treatment using enzyme endonuclease III in the study groups. Data presented as mean ±
standard error of mean. *p < 0.05 – significant difference compared to control group (Gamma distribution).
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to cause guanine than pyrimidine oxidation. It appears
that endonuclease III can give an indication of overall
oxidative damage to DNA, resulting from a variety of
diabetes-related causes, while FPG reflects specifically
the damage resulting from hyperglycemia, namely 8-
oxo-guanine [19].
In the present study we did not detect a significant
difference in the urinary 8-OHdG concentration among
the three groups. However, the values increased accord-
ing to the concentration of glucose, suggesting a rela-
tionship between blood glucose and oxidative stress.
Recently, Qiu et al. [33] showed that a single measure-
ment of urinary 8-OHdG concentrations is not likely to
provide a time-integrated measure of maternal cellular
oxidative stress during the entire pregnancy. Therefore,
longitudinal studies, with serial measurements of urinary
8-OHdG concentrations along with indices of insulin
sensitivity and secretion across gestation, are needed toFigure 3 8-OHdG concentrations (ng/mg creatinine) in the study grou
multiple comparison test). p > 0.05 - No significant difference.elucidate the mechanisms and pathophysiological conse-
quences of maternal oxidative stress during pregnancy.
In conclusion, both diabetic and mild gestational hyper-
glycemia (MGH) pregnant women presented evidence of
increased oxidative DNA damage. However, the specific
DNA base that was mostly affected in the two conditions
were different, purines in diabetic pregnancy and pyrim-
idines in MGH. Taken together, the present data under-
score that hyperglycemia is an important stimulus to
maternal DNA damage and even mild forms of hyper-
glycemia can induce measurable DNA damage and
adverse consequences for pregnant women and their
offspring [4,2,1]. Gestational dysglycemia (diabetes and
MGH) identifies a group of women with higher oxida-
tive DNA damage.
The utility of identifying the unique DNA bases mostly
affected in MGH suggests that this condition is charac-
terized by a group of patients not only with hypergly-
cemia but also with other clinical parameters responsibleps. Data presented as mean ± standard deviation of mean (Tukey’s
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glycemic intensity, affected bases and forms of treat-
ment, hyperglycemic and diabetic groups require strict
medical control in order to control hyperglycemia and
other risk factors such as obesity, insulin resistance and
hypertension by targeted intervention. One goal of
future investigation is to identify screening tools and
biomarkers that may be evident in women with MGH
before the emergence of diabetes.
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